Third Annual Stem Cell Meeting on the Mesa Regen Med Partnering Forum Announces Presenting Companies

Third Annual Stem Cell Meeting on the Mesa Regen Med Partnering Forum Announces 
Presenting Companies 
Meeting to Include 45+ Company Presentations Featuring 75+
Unpartnered Products From 100+ Clinical Stage Programs 
WASHINGTON, DC -- (Marketwired) -- 08/15/13 --  The Alliance for
Regenerative Medicine (ARM), the international organization
representing the interests of the regenerative medicine community,
today announced the presenting companies for its upcoming Stem Cell
Meeting on the Mesa (SCMOM) Regen Med Partnering Forum. The meeting
will include over 45 leading regenerative medicine-focused companies,
including presentations by Athersys (NASDAQ: ATHX), Organovo (NYSE
MKT: ONVO), Osiris (NASDAQ: OSIR) and Sangamo (NASDAQ: SGMO).
Collectively, the more than 45 presenting companies have over 30
products on the market, are conducting more than 100 clinical trials
and are seeking partnerships for more than 75 product candidates. 
The third annual Regen Med Partnering Forum will take place October
14 and 15, 2013 at the Estancia La Jolla Hotel & Spa, La Jolla,
California as part of the SCMOM. Early bird registration for the
meeting will end on August 30, 2013. The SCMOM's eighth Annual
Scientific Symposium will immediately follow the Regen Med Partnering
Forum on October 16, 2013 at the Salk Institute for Biological
Studies. Combined, these meetings will attract over 800 attendees
from around the globe, highlighting the promise and progress of this
rapidly evolving, interdisciplinary field. 
2013 Presenting Companies and Institutions:
 AlloCure, Athersys,
Avita Medical, bluebird bio, BrainStorm Cell Therapeutics, Capricor,
Cellular Dynamics, Centre for Commercialization of Regenerative
Medicine (CCRM), Cord Blood Registry, Cytori, DiscGenics, Fibrocell
Science, GlaxoSmithKline, Histogen, jCyte, Juventas, Lonza, MaxCyte,
Medipost, Mesoblast, Minerva Biotechnologies, Molmed S.P.A., Moores
Cancer Center, Nanofiber Solutions, NeoStem, New York Stem Cell
Foundation, Organogenesis, Organovo, OrthoCyte Corp., Osiris
Therapeutics, PCT, Pluristem Therapeutics, Promethera Biosciences, Q
Therapeutics, Sangamo BioSciences, Shire, SironRX, Stanford
University, StemBioSys, StemCells, Inc., Terumo BCT, TheraBiologics,
TiGenix, ViaCyte. 
The following four companies will provide updates on recent research
and financial achievements, providing further validation and support
for the regenerative medicine field: 
Athersys recently received a SBIR Fast Track grant from the National
Heart, Lung, and Blood Institute, which will provide up to $2.8
million in support of a Phase 2 clinical study evaluating the
administration of MultiStem(R) therapy to patients who have suffered
a heart attack or acute myocardial infarction. The Company currently
has several clinical stage programs involving MultiStem for the
treatment of inflammatory bowel disease, ischemic stroke, damage
caused by myocardial infarction and the prevention of graft versus
host disease. 
Organovo Holdings, Inc. recently closed a $46.6 million public
offering of common stock. Earlier this year, the company presented
data on human liver tissues generated using their breakthrough 3D
bioprinting technology that are truly three-dimensional, being up to
500 microns in thickness in the smallest dimension, and consisting of
multiple cell types arranged in defined spatial patterns that
reproduce key elements of native tissue architecture.  
Osiris Therapeutics, Inc. just this week reported overwhelmingly
positive data from a clinical study in diabetic foot ulcer (DFU)
patients. Grafix(R), the company's commercialized wound care product,
closed three times as many wounds as standard of care -- the largest
relative improvement ever reported in a multi-center, randomized,
controlled clinical trial for DFU. Grafix is a human cellular repair
matrix containing living stem cells for acute and chronic wound
repair. 
Sangamo recently published groundbreaking research in Nature,
demonstrating the use of their zinc finger DNA-binding protein
technology to inactivate the extra chromosome responsible for Down
syndrome (DS). This advance, accomplished in induced pluripotent stem
cells (iPSCs) derived from DS patients, provides a model to study the
basic biology of DS which may enable the development of drugs that
can potentially rebalance the cellular processes and pathologies that
are impacted by this disorder.  
In addition to presentations by cutting-edge companies seeking
partners and investors, the Regen Med Partnering Forum will include
interactive panels addressing critical commercial, scientific,
regulatory and reimbursement issues. One-on-one meetings will also be
scheduled with a state-of-the-art partnering system to connect
participants. The Regen Med Partnering Forum was developed by the
Alliance for Regenerative Medicine (ARM) and the California Institute
for Regenerative Medicine (CIRM) in 2011 and has grown 35% over the
past three years.  
To learn more or to register for the 2013 Stem Cell Meeting on the
Mesa please visit www.stemcellmeetingonthemesa.com. Registration is
complimentary for investors and credentialed members of the media.
Investors and media should contact Laura Parsons or Michelle Linn for
more information. 
About The Alliance for Regenerative Medicine
 The Alliance for
Regenerative Medicine (ARM) is a Washington, DC-based
multi-stakeholder advocacy organization that promotes legislative,
regulatory and reimbursement initiatives necessary to facilitate
access to life-giving advances in regenerative medicine. ARM also
works to increase public understanding of the field and its potential
to transform human healthcare, providing business development and
investor outreach services to support the growth of its member
companies and research organizations. Prior to the formation of ARM
in 2009, there was no advocacy organization operating in Washington,
DC to specifically represent the interests of the companies, research
institutions, investors and patient groups that comprise the entire
regenerative medicine community. Today ARM has more than 140 members
and is the leading global advocacy organization in this field. To
learn more about ARM or to become a member, visit www.alliancerm.org. 
Investor Contact:
Laura Parsons
Alliance for Regenerative Medicine
Phone: 208-841-4334 
Media Contact:
Michelle Linn
Linnden Communications
Phone: 508-362-3087 
 
 
Press spacebar to pause and continue. Press esc to stop.